CANADIAN SURVEILLANCE OF COVID-19 IN PREGNANCY: EPIDEMIOLOGY, MATERNAL AND INFANT OUTCOMES Rapid Response Maternal-Infant Clinical and Biospecimen Access Platform, Canada

Registration Status: Completed

Objective: As the world responds to the COVID-19 pandemic, robust evidence in priority populations is urgently needed to guide clinical care and public health policy. However, there are substantial gaps in knowledge regarding the impact of SARS-CoV-2 on pregnant women and their infants. For example, placental dysfunction and how the infection impacts fetal development is not well understood. Even if SARS-CoV-2 does not transmit transplacentally, fever alone can influence fetal development and placental function leading to adverse fetal and neonatal outcomes. Moreover, the maternal-newborn population requires unique consideration and care due to increased vulnerability to respiratory infections and to medical interventions used to treat infection. Access to maternal and infant biological material is therefore imperative for gaining a more comprehensive understanding of the burden of SARS-CoV-2 on a pregnant population.

Registered Biobank Name CANADIAN SURVEILLANCE OF COVID-19 IN PREGNANCY: EPIDEMIOLOGY, MATERNAL AND INFANT OUTCOMES Rapid Response Maternal-Infant Clinical and Biospecimen Access Platform
Biobank Leader Tiffany Reeve
Country Canada
Email for biobank inquiries tiffany.reeve@cw.bc.ca
Principal Investigator Dr. Deborah Money
Website
User Type
  • Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties
  • Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group
  • Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper
Biospecimen Collected:
Cohort Highlights